Scinai Immunotherapeutics Ltd
Research Scinai Immunotherapeutics Ltd (SCNI) on Bullrun: market cap USD 672.60K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSCNI
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 672.60K
- Financial periodQ2 2026
- RevenueUSD 460.00K
- Net income-USD 2.00M
- Free cash flow-USD 2.58M
- Gross margin-272.2%
Valuation Snapshot
latest market cap is USD 672.60K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.31M | -USD 8.31M | -USD 6.06M | -202.3% | 0 | USD 1.66M | USD 2.27M | USD 8.10M |
| FY2024 | USD 658.00K | USD 4.80M | -USD 6.35M | -88.1% | 0 | USD 1.96M | USD 2.09M | USD 9.98M |
| FY2023 | USD 0 | -USD 6.50M | -USD 10.02M | n/a | 0 | USD 4.87M | USD 20.56M | -USD 4.57M |
| FY2022 | USD 0 | -USD 5.80M | -USD 8.10M | n/a | 0.01 | USD 14.08M | USD 382.00K | -USD 1.76M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 672.60K | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.46M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.86M | 1.2 | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.59M | 0.7 | n/a | n/a |
| 2022 | 2022-12-30 | USD 5.58M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 43.43M | n/a | n/a | n/a |
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Scinai Immunotherapeutics Ltd's market cap?
Scinai Immunotherapeutics Ltd's market capitalization is USD 672.60K.
What does Scinai Immunotherapeutics Ltd do?
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.